The real problem for our ADO management is how to advise the impact of the expected sales revenue from Ellume without disclosing the price per test of the Anteobind supplied (so as not to conflict with any "commercial-in-confidence" agreement with Ellume, and not to limit the price ADO may ask from others).
Not a bad problem to have, but it is a real one that must be dealt with carefully!
Ann out, page-27
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.001(4.35%) |
Mkt cap ! $54.30M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.2¢ | $7.565K | 343.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 725857 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 286098 | 3 |
View Market Depth
| Last trade - 11.08am 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.3¢ |
Change
-0.001 ( 1.32 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.3¢ | 2.2¢ | 257074 | ||
| Last updated 13.04pm 07/06/2024 ? | |||||
| ADO (ASX) Chart |